3 results
This non-controlled multicentric phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase for first-line treatment of infants (< 1 year of age at…
This multicentre phase III study is designed to assess the efficacy and safety of recombinant versus E-Coli derived Aaparaginase from Medac, during treatment of children with newly diagnosed ALL according to the DCOG ALL-10 protocol.Futhermore: To…
The purpose of this study is to investigate how quickly and to what extend JZP-324 is absorbed and eliminated from the body (this is called pharmacokinetics). It will also be investigated how safe the new compound JZP-324 is and how well it is…